Plasma phosphorylated tau181 and neurofilament light chain linked to neurodegeneration in dementia

Takeaway

  • Baseline levels and longitudinal changes in plasma phosphorylated-tau181 levels are associated with future neurodegeneration and cognitive decline in Alzheimer’s disease.

Why this matters

    The ability to monitor disease progression in Alzheimer’s disease is important to enable individualized treatment. These novel findings suggest that plasma phosphorylated tau at threonine 181 is an accessible, minimally invasive biomarker of neurodegeneration and cognitive decline which, unlike plasma neurofilament light chain, is specific for Alzheimer’s disease.